Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.
Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Biostatistics and Research Support, University Medical Center Utrecht, Utrecht, The Netherlands.
Biogen Idec, Boston, Massachusetts, USA.
- Published Article
Journal of Neurology Neurosurgery & Psychiatry
- Publication Date
Oct 30, 2017
Plasma creatinine is an inexpensive and easily accessible biomarker that exhibits less variability between patients with ALS over time and is predictive for the patient's functional status, muscle strength and mortality risk. Plasma creatinine may, therefore, increase the power to detect treatment effects and could be incorporated in future ALS clinical trials as potential surrogate outcome.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/29084868